Identification of map4k4 as a novel suppressor of skeletal muscle differentiation

Molecular and Cellular Biology

Volumn 33, Issue 4, 2013, Pages 678-687

  Wang, Mengxi ^a   Amano, Shinya U ^a   Roth Flach, Rachel J ^a   Chawla, Anil ^a   Aouadi, Myriam ^a   Czech, Michael P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN 4 KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOGENIC FACTOR 5; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUSION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION; GENE SILENCING; MOUSE; MUSCLE DEVELOPMENT; MUSCLE HYPERTROPHY; MYOBLAST; MYOTUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MYOBLASTS; MYOGENIC REGULATORY FACTOR 5; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84873827846     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00618-12     Document Type: Article

References (45)

1. Braun T, Gautel M. 2011. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat. Rev. Mol. Cell Biol. 12:349-361.
2. Molkentin JD, Black BL, Martin JF, Olson EN. 1995. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83:1125-1136.
3. Olson EN, Klein WH. 1994. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 8:1-8.
4. Berkes CA, Tapscott SJ. 2005. MyoD and the transcriptional control of myogenesis. Semin. Cell Dev. Biol. 16:585-595.
5. Hinterberger TJ, Sassoon DA, Rhodes SJ, Konieczny SF. 1991. Expression of the muscle regulatory factor MRF4 during somite and skeletal myofiber development. Dev. Biol. 147:144-156.
6. Kassar-Duchossoy L, Gayraud-Morel B, Gomes D, Rocancourt D, Buckingham M, Shinin V, Tajbakhsh S. 2004. Mrf4 determines skeletal muscle identity in Myf5:Myod double-mutant mice. Nature 431:466-471.
7. Suelves M, Lluis F, Ruiz V, Nebreda AR, Munoz-Canoves P. 2004. Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes. EMBO J. 23:365-375.
8. Sumariwalla VM, Klein WH. 2001. Similar myogenic functions for myogenin and MRF4 but not MyoD in differentiated murine embryonic stem cells. Genesis 30:239-249.
9. Zhang W, Liu HT. 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9-18.
10. Aouadi M, Bost F, Caron L, Laurent K, Le Marchand Brustel Y, Binetruy B. 2006. p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells 24:1399-1406.
11. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binetruy B, Bost F. 2006. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 55:281-289.
12. Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, Dani C, Hofman P, Pages G, Pouyssegur J, Le Marchand-Brustel Y, Binetruy B. 2005. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54:402-411.
13. Wada T, Penninger JM. 2004. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838-2849.
14. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
15. Knight JD, Kothary R. 2011. The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis. Skelet. Muscle 1:29.
16. Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P. 2006. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 16:36-44.
17. Dan I, Watanabe NM, Kusumi A. 2001. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol. 11:220-230.
18. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. 2006. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl. Acad. Sci. U. S. A. 103:3775-3780.
19. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. 2011. shRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin. Cancer Res. 17:710-720.
20. Xue Y, Wang X, Li Z, Gotoh N, Chapman D, Skolnik EY. 2001. Mesodermal patterning defect in mice lacking the Ste20 NCK interacting kinase (NIK). Development 128:1559-1572.
21. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. 2006. p38 and a p38-interacting protein are critical for downregulation of Ecadherin during mouse gastrulation. Cell 125:957-969.
22. Tang X, Guilherme A, Chakladar A, Powelka AM, Konda S, Virbasius JV, Nicoloro SM, Straubhaar J, Czech MP. 2006. An RNA interferencebased screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc. Natl. Acad. Sci. U. S. A. 103:2087-2092.
23. Guntur KV, Guilherme A, Xue L, Chawla A, Czech MP. 2010. Map4k4 negatively regulates peroxisome proliferator-activated receptor (PPAR) gamma protein translation by suppressing the mammalian target of rapamycin (mTOR) signaling pathway in cultured adipocytes. J. Biol. Chem. 285:6595-6603.
24. Bouzakri K, Zierath JR. 2007. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J. Biol. Chem. 282:7783-7789.
25. Tesz GJ, Aouadi M, Prot M, Nicoloro SM, Boutet E, Amano SU, Goller A, Wang M, Guo CA, Salomon WE, Virbasius JV, Baum RA, O'Connor MJ, Jr, Soto E, Ostroff GR, Czech MP. 2011. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436:351-362.
26. Pasut A, Oleynik P, Rudnicki MA. 2012. Isolation of muscle stem cells by fluorescence activated cell sorting cytometry. Methods Mol. Biol. 798:53-64.
27. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
28. Gros J, Manceau M, Thome V, Marcelle C. 2005. A common somitic origin for embryonic muscle progenitors and satellite cells. Nature 435:954-958.
29. Nishiyama T, Kii I, Kudo A. 2004. Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. J. Biol. Chem. 279:47311-47319.
30. Baumgartner M, Sillman AL, Blackwood EM, Srivastava J, Madson N, Schilling JW, Wright JH, Barber DL. 2006. The Nck-interacting kinase phosphorylates ERM proteins for formation of lamellipodium by growth factors. Proc. Natl. Acad. Sci. U. S. A. 103:13391-13396.
31. Cuenda A, Cohen P. 1999. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:4341-4346.
32. Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY, Puri PL. 2000. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol. Cell. Biol. 20:3951-3964.
33. Zetser A, Gredinger E, Bengal E. 1999. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J. Biol. Chem. 274:5193-5200.
34. Khurana A, Dey CS. 2004. Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation. J. Muscle Res. Cell Motil. 25:645-655.
35. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458:1180-1184.
36. Rajan S, Chu Pham Dang H, Djambazian H, Zuzan H, Fedyshyn Y, Ketela T, Moffat J, Hudson TJ, Sladek R. 2012. Analysis of early C2C12 myogenesis identifies stably and differentially expressed transcriptional regulators whose knock-down inhibits myoblast differentiation. Physiol. Genomics 44:183-197.
37. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev. 18:1926-1945.
38. Winter B, Kautzner I, Issinger OG, Arnold HH. 1997. Two putative protein kinase CK2 phosphorylation sites are important for Myf-5 activity. Biol. Chem. 378:1445-1456.
39. Alter J, Rozentzweig D, Bengal E. 2008. Inhibition of myoblast differentiation by tumor necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia inhibitory factor. J. Biol. Chem. 283:23224-23234.
40. Chen SE, Jin B, Li YP. 2007. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am. J. Physiol. Cell Physiol. 292: C1660-C1671.
41. Coletti D, Yang E, Marazzi G, Sassoon D. 2002. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J. 21:631-642.
42. Charge SB, Rudnicki MA. 2004. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 84:209-238.
43. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. 2010. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J. Clin. Invest. 120:11-19.
44. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, Butler-Browne GS. 1999. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. J. Cell Sci. 112:2895-2901.
45. Gayraud-Morel B, Chretien F, Flamant P, Gomes D, Zammit PS, Tajbakhsh S. 2007. A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. Dev. Biol. 312:13-28.